Skip to main content
. Author manuscript; available in PMC: 2018 Sep 21.
Published in final edited form as: Cell Chem Biol. 2017 Sep 21;24(9):1075–1091. doi: 10.1016/j.chembiol.2017.08.002

Figure 3. Advances in the Development of Patient-Derived Models.

Figure 3

Timeline describing key developments in the generation of patient-derived models. Declines in sequencing costs (orange points); and the emergence of model types, including cell lines, xenografts, organoids, and “next-generation” cell lines, are highlighted (source data: Rygaard and Povlsen, 1969; Jeffreys et al., 1985; The Cancer Genome Atlas, 2005; Wetterstrand, 2016; and references cited in the main text).